It has been about a month since the last earnings report for Alnylam Pharmaceuticals, Inc. (ALNY - Free Report) . Shares have added about 14.5% in that time frame, outperforming the market.
Will the recent positive trend continue leading up to the stock's next earnings release, or is it due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important drivers.
Alnylam Q4 Loss Narrower than Expected, Revenues Rise
Alnylam reported a loss of $1.32 per share in the fourth quarter of 2016, narrower than both the Zacks Consensus Estimate loss of $1.35 and the year-ago loss of $1.07.
Quarterly revenues rose 131.1% to $17.5 million. Additionally, revenues were also above the Zacks Consensus Estimate of $11.56 million. Revenues in the quarter included $14.8 million earned under the company's collaboration agreement with Genzyme, as well as $2.6 million from the company’s alliance with The Medicines Company and $0.1 million from other sources.
Quarter in Detail
Research and Development (R&D) expenses shot up 26.8% from the year-ago period to $105 million. The hike was due to higher expenses related to the company’s advancement of the Genetic Medicine pipeline as well as higher compensation and related expensesLikewise, general and administrative (G&A) expenses also increased 61.8% to $27.9 million. The increase was on the back of higher compensation and related expenses as well as consulting and professional services expenses
2016 Results
For the full-year 2016, net loss came in at $4.79 per share compared with a loss of $3.45 in 2015 and narrower than the Zacks Consensus Estimate of $4.82 per share.
Nevertheless, revenues came in at $47.2 million for 2016 compared with $41.1 million in 2015 and also beat the Zacks Consensus Estimate of 40.62 million.
Outlook
Alnylam expects that its cash, cash equivalents and marketable securities, (including restricted investments) will be greater than $700 million as of Dec 31, 2017.
How Have Estimates Been Moving Since Then?
Analysts were quiet during the last one month period as none of them issued any earnings estimate revisions.
VGM Scores
At this time, Alnylam's stock has a poor score of 'F' on both growth and momentum front. Following the exact same course , the stock was allocated a grade of 'F' on the value side, putting it in the fifth quintile for this investment strategy.
Overall, the stock has an aggregate VGM Score of 'F'. If you aren't focused on one strategy, this score is the one you should be interested in.
Our style scores indicate investors will probably be better served looking elsewhere.
Outlook
The stock has a Zacks Rank #3 (Hold). We are expecting an inline return from the stock in the next few months.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
It has been about a month since the last earnings report for Alnylam Pharmaceuticals, Inc. (ALNY - Free Report) . Shares have added about 14.5% in that time frame, outperforming the market.
Will the recent positive trend continue leading up to the stock's next earnings release, or is it due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important drivers.
Alnylam Q4 Loss Narrower than Expected, Revenues Rise
Alnylam reported a loss of $1.32 per share in the fourth quarter of 2016, narrower than both the Zacks Consensus Estimate loss of $1.35 and the year-ago loss of $1.07.
Quarterly revenues rose 131.1% to $17.5 million. Additionally, revenues were also above the Zacks Consensus Estimate of $11.56 million. Revenues in the quarter included $14.8 million earned under the company's collaboration agreement with Genzyme, as well as $2.6 million from the company’s alliance with The Medicines Company and $0.1 million from other sources.
Quarter in Detail
Research and Development (R&D) expenses shot up 26.8% from the year-ago period to $105 million. The hike was due to higher expenses related to the company’s advancement of the Genetic Medicine pipeline as well as higher compensation and related expensesLikewise, general and administrative (G&A) expenses also increased 61.8% to $27.9 million. The increase was on the back of higher compensation and related expenses as well as consulting and professional services expenses
2016 Results
For the full-year 2016, net loss came in at $4.79 per share compared with a loss of $3.45 in 2015 and narrower than the Zacks Consensus Estimate of $4.82 per share.
Nevertheless, revenues came in at $47.2 million for 2016 compared with $41.1 million in 2015 and also beat the Zacks Consensus Estimate of 40.62 million.
Outlook
Alnylam expects that its cash, cash equivalents and marketable securities, (including restricted investments) will be greater than $700 million as of Dec 31, 2017.
How Have Estimates Been Moving Since Then?
Analysts were quiet during the last one month period as none of them issued any earnings estimate revisions.
VGM Scores
At this time, Alnylam's stock has a poor score of 'F' on both growth and momentum front. Following the exact same course , the stock was allocated a grade of 'F' on the value side, putting it in the fifth quintile for this investment strategy.
Overall, the stock has an aggregate VGM Score of 'F'. If you aren't focused on one strategy, this score is the one you should be interested in.
Our style scores indicate investors will probably be better served looking elsewhere.
Outlook
The stock has a Zacks Rank #3 (Hold). We are expecting an inline return from the stock in the next few months.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Get the latest research report on ALNY - FREE